B+
Bull case
0%
Probability
Target price
$255.00
+8.8% vs current
LGND
LigandBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$228.00
-2.7% vs current
B-
Bear case
0%
Probability
Target price
$180.00
-23.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.1
Score
AI commentary
The near-term tone is mixed. Primary company materials support a solid royalty-growth quarter, reaffirmed full-year guidance, and tangible portfolio expansion logic from XOMA, but the immediate market read-through was still shaped by the revenue/EPS miss and a sharp opening gap lower on May 7, 2026. T+3 analyst-revision evidence was not meaningfully visible in the sources checked, so this remains a cautious post-earnings monitoring view rather than a high-conviction bullish reset.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 earnings miss is now offset against reaffirmed full-year guidanceMedium impact
Ligand reported Q1 2026 royalty revenue growth of 56% year over year, but total revenue of $51.7 million and adjusted EPS of $1.63 still trailed the consensus figures visible in checked secondary coverage, while management reaffirmed the previously raised 2026 outlook after the XOMA announcement. The near-term setup is therefore a post-print digestion period where investors decide whether the miss was mainly timing and mark-to-market noise or a signal that the royalty model is less predictable than the premium multiple implies [#8-K-2026-05-07] [#10-Q-2026-05-08].
2026-09-30eventPending XOMA Royalty acquisition is the main 2026 portfolio-expansion triggerHigh impact
Ligand said the XOMA Royalty acquisition is expected to close in Q3 2026 and would add more than 120 assets, including seven commercial assets and 14 late-stage programs, with about $25 million of partial-year royalty revenue contribution assumed in the raised 2026 outlook. If the deal closes on time and integration is clean, it would deepen portfolio scale and diversification; if timing slips or financing and synergy assumptions prove too optimistic, the current growth case loses some of its most visible support [#8-K-2026-05-07].
2026-11-15catalystLate-stage partner asset progress still matters, with Qtorin NDA timing one visible second-half testMedium impact
Ligand highlighted that Palvella's Qtorin rapamycin NDA submission for microcystic lymphatic malformations remains on track for the second half of 2026 after positive Phase 3 data. This is not near-term earnings support, but it does matter for preserving the market view that Ligand can keep stacking new royalty-bearing programs beyond the current commercial leaders [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology